TNGX
Income statement / Annual
Last year (2023), Tango Therapeutics, Inc.'s total revenue was $36.53 M,
an increase of 46.93% from the previous year.
In 2023, Tango Therapeutics, Inc.'s net income was -$101.74 M.
See Tango Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$36.53 M
|
$24.86 M
|
$37.04 M
|
$7.66 M
|
$24.65 M
|
| Cost of Revenue |
$115.20 M |
$4.03 M |
$1.97 M |
$1.63 M |
$32.27 M |
| Gross Profit |
-$78.67 M |
$20.83 M |
$35.08 M |
$6.03 M |
-$7.63 M |
| Gross Profit Ratio |
-2.15 |
0.84 |
0.95 |
0.79 |
-0.31 |
| Research and Development
Expenses |
$115.20 M
|
$105.91 M
|
$77.64 M
|
$49.99 M
|
$32.27 M
|
| General & Administrative
Expenses |
$35.50 M
|
$30.03 M
|
$17.60 M
|
$9.87 M
|
$7.54 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$35.50 M
|
$30.03 M
|
$17.60 M
|
$9.87 M
|
$7.54 M
|
| Other Expenses |
$0.00 |
$2.95 M |
$247,000.00 |
$120,000.00 |
$0.00 |
| Operating Expenses |
$150.70 M |
$135.93 M |
$95.23 M |
$59.86 M |
$7.15 M |
| Cost And Expenses |
$150.70 M |
$135.93 M |
$95.23 M |
$59.86 M |
$39.43 M |
| Interest Income |
$6.62 M |
$1.46 M |
$495,000.00 |
$108,000.00 |
$684,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$2.42 M
|
$4.03 M
|
$1.97 M
|
$1.63 M
|
$643,000.00
|
| EBITDA |
-$111.76 M
|
-$109.46 M
|
-$57.29 M
|
-$51.48 M
|
-$14.52 M
|
| EBITDA Ratio |
-3.06 |
-4.47 |
-1.57 |
-6.72 |
-0.59 |
| Operating Income Ratio
|
-3.13
|
-4.47
|
-1.57
|
-6.82
|
-0.62
|
| Total Other
Income/Expenses Net |
$12.56 M
|
$2.95 M
|
$247,000.00
|
$228,000.00
|
$1.07 M
|
| Income Before Tax |
-$101.61 M |
-$108.12 M |
-$57.94 M |
-$51.97 M |
-$14.10 M |
| Income Before Tax Ratio
|
-2.78
|
-4.35
|
-1.56
|
-6.79
|
-0.57
|
| Income Tax Expense |
$134,000.00 |
$54,000.00 |
$292,000.00 |
-$108,000.00 |
$0.00 |
| Net Income |
-$101.74 M |
-$108.18 M |
-$58.24 M |
-$51.86 M |
-$14.10 M |
| Net Income Ratio |
-2.79 |
-4.35 |
-1.57 |
-6.77 |
-0.57 |
| EPS |
-1.08 |
-1.23 |
-0.94 |
-1.62 |
-1.57 |
| EPS Diluted |
-1.08 |
-1.23 |
-0.94 |
-1.62 |
-1.57 |
| Weighted Average Shares
Out |
$94.57 M
|
$87.82 M
|
$62.11 M
|
$31.93 M
|
$8.99 M
|
| Weighted Average Shares
Out Diluted |
$94.57 M
|
$87.82 M
|
$62.11 M
|
$31.93 M
|
$8.99 M
|
| Link |
|
|
|
|
|
